Iranian patients’ attitudes to current and novel therapies: A patient directed survey

  • Mahmoud Hadipour Dehshal Charity Foundation for Special Diseases, Tehran, Iran, Islamic Republic of.
  • Michael Angastiniotis Thalassaemia International Federation, Nicosia, Cyprus.
  • Sachiko Hosoya School of Nursing at Narita, Public Health Nursing, International University of Health and Welfare, Chiba, Japan.
  • Fatemeh Hashemi Bahremani Charity Foundation for Special Diseases, Tehran, Iran, Islamic Republic of.
  • Mehdi Tabrizi Namini Iranian Blood Transfusion Organization, Tehran, Iran, Islamic Republic of.
  • Androulla Eleftheriou | thalassaemia@cytanet.com.cy Thalassaemia International Federation, Nicosia, Cyprus.

Abstract

Thalassemia is one of the important challenges of the health system in Iran. Recently the medicinal drug of luspatercept and gene therapy have opened new horizons for thalassemia treatment. The present article aims to evaluate the attitude of thalassemics in Iran about the new treatments. In this research, data collection through the virtual space has been practiced. The patients were required to declare their opinion on the aforementioned treatments. Finally, 128 male and 204 female plus 1 who did not specify their gender answered the questions. The results showed that despite patients’ positive attitude towards new treatments, their treatment experiences as well as the expenses of the new treatment practices are cause of concern. Moreover, the social problems like unemployment among thalassemics place impact on their perspective about treatment changes. Based on the findings of the present research, providing patients with more information about new treatment regimen and making the their expenses compatible with the economic status of the developing countries would be effective in making the new treatments accessible to all eligible patients.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2021-03-17
Info
Issue
Section
Original Articles
Keywords:
Thalassaemia, patient perspective, patients point of view, novel therapies, gene therapies, luspatercept.
Statistics
  • Abstract views: 298

  • PDF: 233
How to Cite
Dehshal, M. H., Angastiniotis, M., Hosoya, S., Bahremani, F. H., Namini, M. T., & Eleftheriou, A. (2021). Iranian patients’ attitudes to current and novel therapies: A patient directed survey. Thalassemia Reports, 11(1). https://doi.org/10.4081/thal.2021.9514

Most read articles by the same author(s)